All In Biotech

Drug Trial Radar · NCT04822181

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

The Effect of Semaglutide in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,205 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,205

Actual

Start

Apr 1, 2021

Primary completion

Apr 25, 2029

Study completion Apr 25, 2029

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Mar 30, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. Participants will either get semaglutide or a dummy medicine - which treatment participants get is decided by chance. Participants will need to inject themselves with medicine under the skin. Participants will need to do this once a week. The study will last for about 5 years. Participants will have up to 21 clinic visits and 9 phone calls with the clinical staff during the study. Some of the clinic visits may be spread over more than one day. Participants with other chronic liver diseases cannot take part in this study. Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period.

Conditions

  • Non-alcoholic Steatohepatitis

Interventions

  • SemaglutideDrug

    Semaglutide administrated subcutaneously (under the skin) once weekly there will be a period of dose escalation before reaching the target dose.

  • PlaceboDrug

    Placebo administrated subcutaneously (under the skin) once weekly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Resolution of steatohepatitis and no worsening of liver fibrosis (Yes/No)Time frame: From randomisation (week 0) to week 72
  2. Part 1: Improvement in liver fibrosis and no worsening of steatohepatitis (Yes/No)Time frame: From randomisation (week 0) to week 72
  3. Part 2: Cirrhosis-free survival (Yes/No)Time frame: From randomisation (week 0) to week 240

Locations

558 sites in 39 countries. Site status is shown where the registry gives one.

  • North AL Health Res, LLC

    Huntsville, Alabama

  • The Institute for Liver Health

    Chandler, Arizona

  • Inst-Liver Hlth dba AZ Liver H

    Peoria, Arizona

  • Inst. Liver H II dba AZ Liver H

    Tucson, Arizona

  • Del Sol Research Management, LLC

    Tucson, Arizona

  • ARcare Center for Clinical Research

    Jonesboro, Arkansas

  • ARcare Center for Clinical Research

    Little Rock, Arkansas

  • Arkansas Diagnostic Center, PA

    Little Rock, Arkansas

  • Gastroenterology & Liver Institute

    Escondido, California

  • Shang Wu M.D. Inc.

    Hacienda Heights, California

  • Scripps Whittier Diabetes Inst

    La Jolla, California

  • UCSD NAFLD Research Center

    La Jolla, California

  • OM Research LLC

    Lancaster, California

  • Digestive Hlth Res of SoCa

    Long Beach, California

  • OM Research LLC

    Oxnard, California

  • Cedars-Sinai Medical Center

    Pasadena, California

  • Pasedena Liver Center

    Pasadena, California

  • Inland Empire Clin Trials LLC

    Rialto, California

  • UC Davis Hlth -Midtwn Ambu Cen

    Sacramento, California

  • University of California, San Francisco

    San Francisco, California

  • San Jose Gastroenterology

    San Jose, California

  • Peak Gastro Assoc-Col Springs

    Colorado Springs, Colorado

  • Yale Ctr for Clin Invest

    New Haven, Connecticut

  • Encore Medical Research of Boynton Beach LLC

    Boynton Beach, Florida

  • Integrity Clinical Research, LLC

    Doral, Florida

  • Covenant Metabolic Specialists, Ft. Myers

    Fort Myers, Florida

  • University of Florida-CTRB

    Gainesville, Florida

  • Miguel Rebollar PA

    Hialeah, Florida

  • Direct Helpers Research Center

    Hialeah, Florida

  • Florida Research Institute, LLC

    Lakewood Rch, Florida

  • Sandhill Research, LLC

    Maitland, Florida

  • Tandem Clinical Research - Maitland

    Maitland, Florida

  • Optimus U, Corp

    Miami, Florida

  • Univ of Miami/Schiff Ctr

    Miami, Florida

  • Genoma Research Group, Inc

    Miami, Florida

  • IMIC Inc

    Miami, Florida

  • San Marcus Res Clin Miami Lakes

    Miami Lakes, Florida

  • Ocala GI Research

    Ocala, Florida

  • Sensible Healthcare LLC

    Ocoee, Florida

  • Covenant Metabolic Specialists LLC

    Sarasota, Florida

Showing 40 of 558 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.